CN103328506A - 用于改善肺功能的疗法 - Google Patents

用于改善肺功能的疗法 Download PDF

Info

Publication number
CN103328506A
CN103328506A CN2011800498365A CN201180049836A CN103328506A CN 103328506 A CN103328506 A CN 103328506A CN 2011800498365 A CN2011800498365 A CN 2011800498365A CN 201180049836 A CN201180049836 A CN 201180049836A CN 103328506 A CN103328506 A CN 103328506A
Authority
CN
China
Prior art keywords
antagonist
antibody
seq
composition
purposes
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
CN2011800498365A
Other languages
English (en)
Chinese (zh)
Inventor
R·法奇奥尼
R·梅
C·凯尔
N·摩尔菲诺
L·罗什科斯
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
MedImmune LLC
Original Assignee
MedImmune LLC
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by MedImmune LLC filed Critical MedImmune LLC
Publication of CN103328506A publication Critical patent/CN103328506A/zh
Pending legal-status Critical Current

Links

Images

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/24—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against cytokines, lymphokines or interferons
    • C07K16/244—Interleukins [IL]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61B—DIAGNOSIS; SURGERY; IDENTIFICATION
    • A61B5/00—Measuring for diagnostic purposes; Identification of persons
    • A61B5/08—Measuring devices for evaluating the respiratory organs
    • A61B5/087—Measuring breath flow
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
    • A61K39/3955—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against proteinaceous materials, e.g. enzymes, hormones, lymphokines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/06—Antiasthmatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/08—Antiallergic agents
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
    • G01N33/6863—Cytokines, i.e. immune system proteins modifying a biological response such as cell growth proliferation or differentiation, e.g. TNF, CNF, GM-CSF, lymphotoxin, MIF or their receptors
    • G01N33/6869—Interleukin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
    • G01N2333/435—Assays involving biological materials from specific organisms or of a specific nature from animals; from humans
    • G01N2333/52—Assays involving cytokines
    • G01N2333/54—Interleukins [IL]
    • G01N2333/5437—IL-13
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2800/00—Detection or diagnosis of diseases
    • G01N2800/12—Pulmonary diseases
    • G01N2800/122—Chronic or obstructive airway disorders, e.g. asthma COPD

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Immunology (AREA)
  • Molecular Biology (AREA)
  • Organic Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Biomedical Technology (AREA)
  • Pulmonology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Hematology (AREA)
  • Biochemistry (AREA)
  • Urology & Nephrology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Cell Biology (AREA)
  • Physics & Mathematics (AREA)
  • Biophysics (AREA)
  • Pathology (AREA)
  • Microbiology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Epidemiology (AREA)
  • Food Science & Technology (AREA)
  • Genetics & Genomics (AREA)
  • General Physics & Mathematics (AREA)
  • Biotechnology (AREA)
  • Analytical Chemistry (AREA)
  • Medical Informatics (AREA)
  • Physiology (AREA)
  • Surgery (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Endocrinology (AREA)
  • Mycology (AREA)
CN2011800498365A 2010-10-15 2011-10-14 用于改善肺功能的疗法 Pending CN103328506A (zh)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
US39367710P 2010-10-15 2010-10-15
US61/393,677 2010-10-15
US201161508723P 2011-07-18 2011-07-18
US61/508,723 2011-07-18
PCT/EP2011/067947 WO2012049278A1 (en) 2010-10-15 2011-10-14 Therapies for improving pulmonary function

Publications (1)

Publication Number Publication Date
CN103328506A true CN103328506A (zh) 2013-09-25

Family

ID=44800047

Family Applications (1)

Application Number Title Priority Date Filing Date
CN2011800498365A Pending CN103328506A (zh) 2010-10-15 2011-10-14 用于改善肺功能的疗法

Country Status (15)

Country Link
US (1) US20130281876A1 (enExample)
EP (1) EP2627673B1 (enExample)
JP (1) JP2013544235A (enExample)
CN (1) CN103328506A (enExample)
AU (1) AU2011315499A1 (enExample)
BR (1) BR112013009055A2 (enExample)
CA (1) CA2814431A1 (enExample)
DK (1) DK2627673T3 (enExample)
ES (1) ES2645368T3 (enExample)
HU (1) HUE034005T2 (enExample)
MX (1) MX2013004212A (enExample)
NO (1) NO2627673T3 (enExample)
PL (1) PL2627673T3 (enExample)
RU (1) RU2013122123A (enExample)
WO (1) WO2012049278A1 (enExample)

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN105636607A (zh) * 2013-10-15 2016-06-01 免疫医疗有限责任公司 用于使用贝那利珠单抗治疗慢性阻塞性肺疾病的方法

Families Citing this family (17)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR102502640B1 (ko) 2012-08-21 2023-02-23 사노피 바이오테크놀로지 Il-4r 길항제의 투여에 의한 천식의 치료 또는 예방 방법
WO2015112970A1 (en) * 2014-01-27 2015-07-30 Medimmune, Llc Dipeptidyl peptidase-4 (dpp4/cd26) as a peripheral biomarker of il-13 activation in asthmatic lung
IL315136A (en) * 2014-02-21 2024-10-01 Sanofi Biotechnology Methods for treating or preventing asthma by administering an il-4rantagonist
EP3129497B1 (en) 2014-04-11 2021-09-08 Novartis AG Methods of selectively treating asthma using il-13 antagonists
CA3246946A1 (en) 2014-11-14 2025-11-29 Sanofi Biotechnology Methods for treating chronic sinusitis with nasal polyps by administering an il-4r antagonist
AU2016205188A1 (en) 2015-01-09 2017-06-22 Medimmune, Llc Assay to detect human DPP-4
CN104605857A (zh) * 2015-02-12 2015-05-13 上海朔茂网络科技有限公司 一种肺功能测量方法
WO2017189805A1 (en) 2016-04-27 2017-11-02 Abbvie Inc. Methods of treatment of diseases in which il-13 activity is detrimental using anti-il-13 antibodies
JP2020509025A (ja) * 2017-03-01 2020-03-26 メドイミューン・リミテッドＭｅｄＩｍｍｕｎｅ Ｌｉｍｉｔｅｄ モノクローナル抗体製剤
WO2019028367A1 (en) 2017-08-04 2019-02-07 Regeneron Pharmaceuticals, Inc. METHODS OF TREATING ESOPHAGITIS WITH ACTIVE EOSINOPHILES
MA55204A (fr) 2019-03-06 2022-01-12 Regeneron Pharma Inhibiteurs de la voie il-4/il-13 pour une efficacité améliorée dans le traitement du cancer
KR20210143246A (ko) 2019-03-21 2021-11-26 리제너론 파아마슈티컬스, 인크. 알레르기 치료용 il-4/il-13 경로 억제제 및 형질 세포 절제의 병용
KR20220034878A (ko) 2019-07-16 2022-03-18 사노피 바이오테크놀로지 Il-4r 길항제를 투여하여 천식을 치료 또는 예방하는 방법
WO2022026922A2 (en) * 2020-07-31 2022-02-03 Genentech, Inc. Methods for treating exacerbations of inflammatory respiratory diseases
CN112341543B (zh) * 2021-01-11 2021-04-23 广东赛尔生物科技有限公司 包含间充质干细胞外泌体的药物组合物在治疗疾病中的应用
JP2025501239A (ja) 2021-12-30 2025-01-17 リジェネロン・ファーマシューティカルズ・インコーポレイテッド Ｉｌ－４／ｉｌ－１３アンタゴニストを投与することによってアトピーマーチを減弱する方法
WO2026151705A1 (en) * 2025-01-07 2026-07-16 Apogee Therapeutics, Inc. Dosage and administration of interleukin-13 antibody to treat asthma

Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2006055638A2 (en) * 2004-11-17 2006-05-26 Abgenix, Inc. Fully human monoclonal antibodies to il-13
CN1852923A (zh) * 2003-07-15 2006-10-25 剑桥抗体科技有限公司 针对il－13的人抗体分子
CN101370829A (zh) * 2006-01-11 2009-02-18 葛兰素集团有限公司 嵌合和人源化的抗-人il-13抗体

Family Cites Families (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA2140660A1 (en) * 1993-06-13 1994-12-22 Uwe R. Juergens Use of terpene compounds for reduced release of arachidonic acid and of inflammation mediators
GB0004016D0 (en) 2000-02-22 2000-04-12 Royal Brompton Hospital Biological material and uses thereof

Patent Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN1852923A (zh) * 2003-07-15 2006-10-25 剑桥抗体科技有限公司 针对il－13的人抗体分子
WO2006055638A2 (en) * 2004-11-17 2006-05-26 Abgenix, Inc. Fully human monoclonal antibodies to il-13
CN101370829A (zh) * 2006-01-11 2009-02-18 葛兰素集团有限公司 嵌合和人源化的抗-人il-13抗体

Non-Patent Citations (2)

* Cited by examiner, † Cited by third party
Title
CLINICAL TRIALS.GOV: "A Phase 2a, Randomized, Double-blind，Placebo-Controlled，Parallel-Arm， Multicenter Study to Evaluate the Efficacy and Safety of CAT-354，on Asthma Control in Adults", 《CLINICAL TRIALS.GOVNCT00873860》, 24 August 2010 (2010-08-24) *
DAVE SINGH ET AL: "A phase 1 study evaluating the pharmacokinetics,safety and tolerability of repeat dosing with a human IL-13 antibody (CAT-354) in subjects with asthma", 《BMC PULMONARY MEDICINE》, vol. 10, no. 1, 8 January 2010 (2010-01-08), XP021067289 *

Cited By (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN105636607A (zh) * 2013-10-15 2016-06-01 免疫医疗有限责任公司 用于使用贝那利珠单抗治疗慢性阻塞性肺疾病的方法
CN113230399A (zh) * 2013-10-15 2021-08-10 阿斯利康(瑞典)有限公司 用于使用贝那利珠单抗治疗慢性阻塞性肺疾病的方法

Also Published As

Publication number Publication date
HUE034005T2 (en) 2018-01-29
EP2627673A1 (en) 2013-08-21
BR112013009055A2 (pt) 2016-07-19
EP2627673B1 (en) 2017-07-26
DK2627673T3 (da) 2017-11-06
NO2627673T3 (enExample) 2017-12-23
US20130281876A1 (en) 2013-10-24
MX2013004212A (es) 2013-09-02
RU2013122123A (ru) 2014-11-20
JP2013544235A (ja) 2013-12-12
PL2627673T3 (pl) 2018-01-31
WO2012049278A1 (en) 2012-04-19
ES2645368T3 (es) 2017-12-05
CA2814431A1 (en) 2012-04-19
AU2011315499A1 (en) 2013-05-02

Similar Documents

Publication Publication Date Title
EP2627673B1 (en) Therapies for improving pulmonary function
Hodsman et al. A phase 1, randomized, placebo‐controlled, dose‐escalation study of an anti‐IL‐13 monoclonal antibody in healthy subjects and mild asthmatics
JP2013544235A5 (enExample)
JP2017509692A5 (enExample)
JP7591691B2 (ja) 抗インターロイキン－３３抗体による慢性閉塞性肺疾患の処置
JP2022526524A (ja) 喘息の処置のためのリポカリンムテイン
CN115867577A (zh) 用于预测covid-19肺炎中对il-6拮抗剂反应的生物标志物
TW201842933A (zh) 使用il-17拮抗劑選擇性治療氣喘的方法
JP5175198B2 (ja) インターフェロンを用いる肺疾患の処置方法
HK1188603A (en) Therapies for improving pulmonary function
HK1188603B (en) Therapies for improving pulmonary function
TW202544036A (zh) 用抗ｔｓｌｐ抗體治療慢性阻塞性肺病
US20250002598A1 (en) Methods of Treating Asthma with Anti-LIGHT Antibodies
WO2025120567A1 (en) Method of treatment of asthma
HK40114122A (en) Methods of treating asthma with anti-light antibodies
JP2012193207A (ja) インターフェロンを用いる肺疾患の処置方法
WO2024146630A1 (zh) 一种tslp抗体治疗哮喘的方法
CN118488968A (zh) 用抗light抗体治疗哮喘的方法
Shrimanker et al. Protein Therapeutics in Respiratory Medicine
JP2015057446A (ja) インターフェロンを用いる肺疾患の処置方法
KR20080093016A (ko) 인터페론을 사용하여 폐질환을 치료하는 방법

Legal Events

Date Code Title Description
C06 Publication
PB01 Publication
C10 Entry into substantive examination
SE01 Entry into force of request for substantive examination
C02 Deemed withdrawal of patent application after publication (patent law 2001)
WD01 Invention patent application deemed withdrawn after publication

Application publication date: 20130925